Скачать или смотреть Is HIMS Stock a Buy Now? 52-Week Low & Earnings Prediction

Hims & Hers Health Inc. (HIMS) is facing a massive turning point after hitting a new 52-week low of $23.16. Following the bold launch of a $49 monthly compounded Wegovy pill, the company is now locked in a legal standoff with pharma giant Novo Nordisk. With Q4 earnings scheduled for February 23, 2026, investors are scrambling to decide if this 42% yearly decline is a bottom or a trap. We break down the technical support levels, the "knockoff" drug controversy, and the bull vs. bear case for 2026.

Queries & Topics Covered:
HIMS stock news today, Hims & Hers price prediction 2026, HIMS weight loss pill launch, Novo Nordisk vs Hims lawsuit, HIMS earnings date February 2026, best telehealth stocks to buy, HIMS stock analysis, why is HIMS falling, HIMS short interest, compounded GLP-1 legal risks, HIMS price target 2025.

Timestamps:
00:00 HIMS Stock News: The $49 Wegovy Controversy
02:15 Technical Analysis: Support Levels at 52-Week Lows
04:45 Analyst Ratings & February 23rd Earnings Preview
07:10 Final Verdict: Undervalued Growth or Value Trap?

#HIMS #HimsAndHers #StockMarket #Telehealth #Wegovy #Investing #StockAnalysis #GrowthStocks